» Articles » PMID: 20300555

Is There a Predisposition Gene for Ewing's Sarcoma?

Overview
Journal J Oncol
Specialty Oncology
Date 2010 Mar 20
PMID 20300555
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Ewing's sarcoma is a highly malignant tumor of children and young adults. The molecular mechanisms that underlie Ewing's Sarcoma development are beginning to be understood. For example, most cases of this disease harbor somatic chromosomal translocations that fuse the EWSR1 gene on chromosome 22 with members of the ETS family. While some cooperative genetic events have been identified, such as mutations in TP53 or deletions of the CDKN2A locus, these appear to be absent in the vast majority of cases. It is therefore uncertain whether EWS/ETS translocations are the only consistently present alteration in this tumor, or whether there are other recurrent abnormalities yet to be discovered. One method to discover such mutations is to identify familial cases of Ewing's sarcoma and to then map the susceptibility locus using traditional genetic mapping techniques. Although cases of sibling pairs with Ewing's sarcoma exist, familial cases of Ewing's sarcoma have not been reported. While Ewing's sarcoma has been reported as a 2nd malignancy after retinoblastoma, significant associations of Ewing's sarcoma with classic tumor susceptibility syndromes have not been identified. We will review the current evidence, or lack thereof, regarding the potential of a heritable condition predisposing to Ewing's sarcoma.

Citing Articles

Optimal Delivery of Follow-Up Care Following Treatment for Adults Treated for Ewing Sarcoma.

Digklia A, Dolcan A, Kucharczyk M, Jones R, Napolitano A Cancer Manag Res. 2023; 15:537-545.

PMID: 37351338 PMC: 10284160. DOI: 10.2147/CMAR.S362693.


Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates.

Roundhill E, Pantziarka P, Liddle D, Shaw L, Albadrani G, Burchill S Cancers (Basel). 2023; 15(3).

PMID: 36765727 PMC: 9913297. DOI: 10.3390/cancers15030769.


Ewing Sarcoma as Secondary Malignant Neoplasm-Epidemiological and Clinical Analysis of an International Trial Registry.

Zollner S, Kauertz K, Kaiser I, Kerkhoff M, Schaefer C, Tassius M Cancers (Basel). 2022; 14(23).

PMID: 36497417 PMC: 9735743. DOI: 10.3390/cancers14235935.


Identification of an RNA-Binding-Protein-Based Prognostic Model for Ewing Sarcoma.

Chen Y, Su H, Su Y, Zhang Y, Lin Y, Haglund F Cancers (Basel). 2021; 13(15).

PMID: 34359637 PMC: 8345188. DOI: 10.3390/cancers13153736.


Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells.

Sole A, Grossetete S, Heintze M, Babin L, Zaidi S, Revy P Cancer Res. 2021; 81(19):4994-5006.

PMID: 34341072 PMC: 8487988. DOI: 10.1158/0008-5472.CAN-20-3837.


References
1.
Sorensen P, Lessnick S, Liu X, Triche T, Denny C . A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994; 6(2):146-51. DOI: 10.1038/ng0294-146. View

2.
Kinsey M, Smith R, Lessnick S . NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res. 2006; 4(11):851-9. DOI: 10.1158/1541-7786.MCR-06-0090. View

3.
Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y . Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000; 120(2):91-8. DOI: 10.1016/s0165-4608(99)00255-1. View

4.
Guo W, Xu W, Huvos A, Healey J, Feng C . Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl). 2001; 112(12):1101-4. View

5.
Lessnick S, Braun B, Denny C, May W . Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene. 1995; 10(3):423-31. View